The Ropivacaine infusion system is pre-filled, ready to use at the point of care
BioQ Pharma Incorporated, a specialty pharmaceutical company focused on the development and commercialization of single-use, large-volume ready-to-use infusible pharmaceuticals, and Cipla has announced the signing of a strategic distribution, supply and development agreement for the registration and commercialization of BioQ Pharma's Ropivacaine infusion pharmaceutical in India.
BioQ Pharma's unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care. In particular, the Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution.
Mr Josh Kriesel, president and CEO of BioQ Pharma, said, "We are excited to collaborate with Cipla as we expand our worldwide commercial footprint into India. We believe India is an excellent market to help expand our objective of establishing a new standard of care in the presentation and administration of infusible pharmaceuticals. Cipla's proven, hospital-focused sales and marketing organization will be essential in introducing BioQ Pharma's proprietary unit-dose, large volume infusion pharmaceuticals to India's healthcare market, which we believe will benefit from our product's value-add proposition of increased safety, sterility and convenience."
Mr Nikhil Chopra, head of Cipla's India Business, added, "We are very pleased to partner with BioQ Pharma in introducing the Ropivacaine unit-dose infusion system to patients and caregivers in India. We believe that this innovative product represents a significant evolution in enhancing the delivery of infusions and managing post-surgical pain."